From real-world data to digital therapeutics, this MVP Technology Framework evaluates the tech solutions pharmaceutical companies and contract research organizations (CROs) like Pfizer and IQVIA are using to develop and deliver personalized medicine.
We outline the market outlook for remote patient monitoring in clinical research, pharma, and healthcare — from investment trends, to leading companies, to recommendations for players in the space.
We outline the market outlook for digital twins and biosimulations in clinical research, pharma, and healthcare — from investment trends, to leading companies, to recommendations for players in the space.
We outline the market outlook for real-world data in clinical research, pharma, and healthcare — from investment trends, to leading companies, to recommendations for players in the space.
We outline the market outlook for patient recruitment and enrollment in the clinical research, pharma, and healthcare industry — from investment trends, to leading companies, to recommendations for the players in the space.
We outline the market outlook for clinical trial site management software in clinical research, pharma, and healthcare — from market size, to leading companies, to recommendations for players in the space.
We dive into the evolution of clinical trials and where the space is going next, from AI to improve recruitment to in silico trials with simulated patients.
Curebase plans to use the funds to move further into the pharma and biotech spaces. Here are the top-line bullets you need to know.
The company was last valued at $2.2B in August 2021. Here are the top-line bullets you need to know.
Mendel.ai plans to use the funds to accelerate the launch of its clinical information consolidation tool. Here are the top-line bullets you need to know.
This report uses the CB Insights MVP Technology Framework to rank tech market planning decisions and give an adoption playbook for the clinical trials domain.
From precision medicine to genetic screening, here’s how Illumina is being unbundled.
This report looks at the clinical trials tech companies serving pharmaceutical companies and CROs.
Owkin has raised $254.1M in funding to date. Here are the top-line bullets you need to know.
Medable plans to use the funding to help its clients accelerate drug development. Here are the top-line bullets you need to know.
The Series C funding helps TrialSpark reach a $1B valuation. Here are the top-line bullets you need to know.
The funding helps Reify Health’s valuation hit the $2.2B mark. Here are the top-line bullets you need to know.
Big tech is coming for pharma. We analyze Amazon, Microsoft, Apple, and Google’s strategies and priorities across the pharmaceutical value chain.
The funding will help Castor EDC to roll out its direct-to-patient clinical trials services globally. Here are the top-line bullets you need to know.
The funding will help 4G Clinical accelerate its global expansion. Here are the top-line bullets you need to know.
The company plans to use the funding to scale its operations. Here are the top-line bullets you need to know.
The funding will be used to quadruple its team by Q1'22. Here are the top-line bullets you need to know.
Testing new drugs is a slow and expensive process. AI has the potential to disrupt clinical trials — from patient recruitment to adherence monitoring and data collection — and Covid-19 has catalyzed its adoption.
From basic testing to clinical trials, here’s how LabCorp is being unbundled.
Reeling from Covid-19’s widespread disruption, healthcare players are turning to partnerships to strengthen their clinical trial capabilities. We use CB Insights Business Relationships data to analyze what this signals about the future of clinical trials.